Originally published by our sister publication Pain Medicine News
The FDA approved relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg (Myfembree, Myovant and Pfizer) as a once-daily therapy for the management of moderate to severe pain associated with endometriosis in premenopausal women, with a treatment duration of up to 24 months.
The approval is supported by one-year data from the phase 3 SPIRIT program, which included two 24-week multinational clinical studies (SPIRIT 1